EMERALD HEALTH THERAPEUTICS, INC ("EMH")
BULLETIN TYPE: Prospectus- Unit Offering
BULLETIN DATE: February 21, 2017
TSX Venture Tier 2 Company
The Company's Amended and Restated Preliminary Short Form Base Shelf Prospectus dated January 17, 2017 and the Company's Final Preliminary Base Shelf Prospectus dated January 25, 2017 (the "Prospectuses") were filed with and accepted by the TSX Venture Exchange, and were filed with and receipted by the British Columbia Securities Commission on behalf of the Alberta, Saskatchewan, Manitoba, New Brunswick, Nova Scotia, Prince Edward Island and Newfoundland and Labrador securities commissions and were files and receipted by the Ontario Securities Commission, pursuant to the provisions of the applicable securities Acts. The Company filed a prospectus supplement (the "Prospectus Supplement") with the securities commission in each of the provinces of Canada except Quebec on February 3, 2017.
TSX Venture Exchange has been advised that closing of the offering under the Prospectus Supplement occurred on February 10, 2017, for gross proceeds of $13,817,250.
Agents: Dundee Capital Partners
Offering: 10,235,000 units. Each unit consisting of one share and one half of one common share purchase warrant (each full warrant, a "Warrant")
Unit Price: $1.35 per unit
Warrant Exercise Price/Term: $2.00 per share to February 10, 2019.
Agents' Options: 307,050 options exercisable to purchase one unit at $1.35 per unit to February 10, 2019.
For further information, please refer to the Company's Prospectuses and the Prospectus Supplement.
________________________________________
|
|
